GlassScriptPhysician profile
Roshan Patel
NPI 1457709131
$15,523.75
in general payments reported to CMS, 2019-2025
39 companies · $4,546 in 2025
The $4,546 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.15 · 2021: $53.74 · 2022: $1,876 · 2023: $4,049 · 2024: $4,975 · 2025: $4,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,898.42 |
| Education | $671.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,363.99 | 2022-2025 | Evenity, Krystexxa, Otezla |
| Abbvie INC. | $1,979.80 | 2021-2025 | |
| Janssen Biotech, INC. | $1,662.76 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,615.18 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,358.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,306.67 | 2022-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $645.65 | 2022-2025 | Acthar |
| Organon LLC | $466.11 | 2023-2025 | Hadlima |
| Radius Health, INC. | $457.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $447.81 | 2022-2024 | Saphnelo, Evusheld |
| Alexion Pharmaceuticals, INC. | $426.17 | 2022-2025 | Strensiq, Ultomiris |
| Fresenius Kabi USA, LLC | $255.51 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $252.52 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Horizon Therapeutics Plc | $209.59 | 2021-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $198.99 | 2024-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.72 | 2022-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.44 | 2023-2025 | Cyltezo, Ofev |
| Aurinia Pharma U.S., INC. | $180.30 | 2022-2025 | Lupkynis |
| Pfizer INC. | $177.55 | 2022-2025 | |
| Coloplast Corp | $147.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.31 | 2023-2025 | Orencia |
| Novo Nordisk INC | $121.81 | 2024 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $106.75 | 2023 | Reditrex |
| Currax Pharmaceuticals LLC | $106.63 | 2022-2025 | Contrave |
| Genzyme Corporation | $86.47 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.78 | 2024-2025 | Bridion |
| Sobi, INC | $54.31 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $54.20 | 2024 | |
| Verona Pharma, INC. | $49.07 | 2025 | Ohtuvayre |
| Tonix Medicines, INC. | $39.08 | 2025 | Tonmya |
| Celltrion USA INC. | $37.18 | 2023 | Yuflyma |
| Fidia Pharma USA INC. | $34.87 | 2025 | Hymovis, Triluron |
| Jazz Pharmaceuticals INC. | $24.15 | 2019 | |
| Oyster Point Pharma, INC. | $21.88 | 2025 | Tyrvaya |
| Pacira Pharmaceuticals Incorporated | $19.93 | 2023 | Iovera, Zilretta |
| Kyowa Kirin, INC. | $16.19 | 2024 | Crysvita |
| Impel Pharmaceuticals INC. | $16.01 | 2023 | Trudhesa |
| Alvogen INC | $14.13 | 2025 | Teriparatide |
| Hikma Pharmaceuticals USA | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.